Vanguard Capital Management Acquires 5.12% Stake in Rani Therapeutics Holdings Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, disclosing a new 5.12% ownership stake in Rani Therapeutics Holdings Inc (RANI). As of the event date on March 31, 2026, Vanguard beneficially owns 5,109,368 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 5,109,368 shares, while maintaining sole voting power over 486,801 shares. This position was previously reported as zero, marking a significant entry into the issuer's equity. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The filing includes holdings by various Vanguard affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. No other single person's interest in these securities exceeds 5%. This filing establishes Vanguard as a major institutional shareholder in the San Jose-based biotechnology company.